menu
    • menu
    [{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Isoprocin Prodrug","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Reunion Neuroscience","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Reunion Neuroscience \/ MPM BioImpact","highestDevelopmentStatusID":"6","companyTruncated":"Reunion Neuroscience \/ MPM BioImpact"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"RE104","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ MPM BioImpact","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ MPM BioImpact"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RE104","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Reunion Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Reunion Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Seleni Institute","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"RE104","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Reunion Neuroscience \/ Seleni Institute","highestDevelopmentStatusID":"14","companyTruncated":"Reunion Neuroscience \/ Seleni Institute"}]

    Find Clinical Drug Pipeline Developments & Deals by Reunion Neuroscience

    Menu

    Reunion Neuroscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Reunion Neuroscience

                            Canada arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Reunion Neuroscience

                            Canada arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RE104

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Seleni Institute

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Reunion Neuroscience And Seleni Institute Partner on Maternal Mental Health

                            Details : This partnership will grant Reunion Neuroscience access to the Seleni Institute for advancing a mid-stage trial evaluating lead candidate RE104 in Postpartum Depression.

                            Brand Name : RE104

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 09, 2024

                            Lead Product(s) : RE104

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Seleni Institute

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Reunion Neuroscience

                            Canada arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Reunion Neuroscience

                            Canada arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RE104

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Reunion Neuroscience Doses 1st Patient in Phase 2 Trial of RE104 for Postpartum Depression

                            Details : Reunion Neuroscience's lead product RE104, prodrug of 4-OH-DiPT is being evaluated in the mid-stage clinical trial studies for the treatment of postpartum depression

                            Brand Name : RE104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 23, 2024

                            Lead Product(s) : RE104

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Reunion Neuroscience

                            Canada arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Reunion Neuroscience

                            Canada arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RE104

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : MPM BioImpact

                            Deal Size : $103.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Reunion Neuroscience Announces Series A Financing by MPM BioImpact and Novo Holdings

                            Details : The financing will bolster the company's mid-stage trial candiditate, particularly focusing on RE104 in postpartum depression, as well as facilitate expansion into additional psychiatric indications.

                            Brand Name : RE104

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 02, 2024

                            Lead Product(s) : RE104

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : MPM BioImpact

                            Deal Size : $103.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Reunion Neuroscience

                            Canada arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Reunion Neuroscience

                            Canada arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoprocin Prodrug

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : MPM BioImpact

                            Deal Size : $13.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

                            Details : MPM BioImpact will develop next-generation solutions for underserved mental health conditions including, RE104, a proprietary, novel, serotonergic psychedelic compound and the only 4-OH-DiPT prodrug in clinical development, being developed for postpartum...

                            Brand Name : RE104

                            Molecule Type : Small molecule

                            Upfront Cash : $13.1 million

                            June 01, 2023

                            Lead Product(s) : Isoprocin Prodrug

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : MPM BioImpact

                            Deal Size : $13.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth